{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T02:06:58Z","timestamp":1788660418941,"version":"build-2803163510"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"\n Importance<\/jats:title>\n There is ongoing controversy about the adverse events of finasteride, a drug used in the management of alopecia and benign prostatic hyperplasia (BPH). In 2012, reports started emerging on men who had used finasteride and either attempted or completed suicide.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with finasteride use.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This pharmacovigilance case-noncase study used disproportionality analysis (case-noncase design) to detect signals of adverse reaction of interest reported with finasteride in VigiBase, the World Health Organization\u2019s global database of individual case safety reports. To explore the strength of association, the reporting odds ratio (ROR), a surrogate measure of association used in disproportionality analysis, was used. Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (\u226445 and &gt;45 years); comparing finasteride signals with those of drugs with different mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochloride for BPH); comparing finasteride with a drug with a similar mechanism of action and adverse event profile (dutasteride); and comparing reports of suicidality before and after 2012. Data were obtained in June 2019 and analyzed from January 25 to February 28, 2020.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Reported finasteride use.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Suicidality and psychological adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n VigiBase contained 356 reports of suicidality and 2926 reports of psychological adverse events (total of 3282 adverse events of interest) in finasteride users (3206 male [98.9%]; 615 of 868 [70.9%] with data available aged 18-44 years). A significant disproportionality signal for suicidality (ROR, 1.63; 95% CI, 1.47-1.81) and psychological adverse events (ROR, 4.33; 95% CI, 4.17-4.49) in finasteride was identified. In sensitivity analyses, younger patients (ROR, 3.47; 95% CI, 2.90-4.15) and those with alopecia (ROR, 2.06; 95% CI, 1.81-2.34) had significant disproportionality signals for increased suicidality; such signals were not detected in older patients with BPH. Sensitivity analyses also showed that the reports of these adverse events significantly increased after 2012 (ROR, 2.13; 95% CI, 1.91-2.39).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia. The sensitivity analyses suggest that these disproportional signals of adverse events may be due to stimulated reporting and\/or younger patients being more vulnerable to finasteride\u2019s adverse effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2020.3385","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T11:34:33Z","timestamp":1605094473000},"page":"35","source":"Crossref","is-referenced-by-count":111,"title":["Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride"],"prefix":"10.1001","volume":"157","author":[{"given":"David-Dan","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Faculty of Medicine, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Marchese","sequence":"additional","affiliation":[{"name":"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene B.","family":"Cone","sequence":"additional","affiliation":[{"name":"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paciotti","sequence":"additional","affiliation":[{"name":"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health: Aging and Metabolism, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Bhojani","sequence":"additional","affiliation":[{"name":"Division of Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[{"name":"Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi200055r1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bjd.2010.164.issue-1","article-title":"S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents.","volume":"164","author":"Blume-Peytavi","year":"2011","journal-title":"Br J Dermatol"},{"key":"doi200055r2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/ddg.2011.9.issue-s6","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men.","volume":"9","author":"Blumeyer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"doi200055r3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5489\/cuaj.5616","article-title":"Canadian Urological Association guideline on male lower urinary tract symptoms\/benign prostatic hyperplasia (MLUTS\/BPH): 2018 update.","volume":"12","author":"Nickel","year":"2018","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"doi200055r4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"doi200055r5","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia.","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"doi200055r16","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","article-title":"Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.","volume":"95","author":"Uzunova","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"doi200055r17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.pbb.2006.06.016","article-title":"Neurosteroids, neuroactive steroids, and symptoms of affective disorders.","volume":"84","author":"Dubrovsky","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"doi200055r18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5a-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"issue":"5","key":"doi200055r19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","article-title":"Association of suicidality and depression with 5a-reductase inhibitors.","volume":"177","author":"Welk","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"12","key":"doi200055r20","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1210\/jc.2016-2726","article-title":"Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.","volume":"101","author":"Basaria","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"doi200055r21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11255-015-0920-5","article-title":"Depressive symptoms in patients diagnosed with benign prostatic hyperplasia.","volume":"47","author":"Pietrzyk","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"doi200055r22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2015.36","article-title":"Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis.","volume":"151","author":"Belknap","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi200055r23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: a prospective study.","volume":"6","author":"Rahimi-Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"issue":"7","key":"doi200055r24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study.","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"13","key":"doi200055r26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib.","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"doi200055r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA: inspection of US American adverse drug events pharmacovigilance data and novel clinical applications.","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"doi200055r28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"doi200055r29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/0253-7613.157102","article-title":"Pharmacovigilance: a data mining approach to signal detection.","volume":"47","author":"Chakraborty","year":"2015","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"doi200055r30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.2020.38.6_suppl.70","article-title":"Association of abiraterone and higher odds of cardiac complications compared to enzalutamide.","volume":"38","author":"Cone","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"doi200055r31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/pds.v26.10","article-title":"Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.","volume":"26","author":"Motola","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"doi200055r32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting.","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"doi200055r33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions.","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf"},{"issue":"8","key":"doi200055r34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/(ISSN)1099-1557","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"doi200055r35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system.","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat."},{"issue":"11","key":"doi200055r36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US Food and Drug Administration\u2013issued alerts on the adverse event reporting system (FAERS).","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"doi200055r37","doi-asserted-by":"publisher","first-page":"m575","DOI":"10.1136\/bmj.m575","article-title":"Association between suicide reporting in the media and suicide: systematic review and meta-analysis.","volume":"368","author":"Niederkrotenthaler","year":"2020","journal-title":"BMJ"},{"key":"doi200055r38","author":"Nickel","year":"2004","journal-title":"Rev Urol"},{"issue":"5","key":"doi200055r39","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor.","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"doi200055r40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"issue":"9","key":"doi200055r41","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"doi200055r45","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss.","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"issue":"1","key":"doi200055r46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jaad.2019.03.043","article-title":"Sexual dysfunction in men taking systemic dermatologic medication: a systematic review.","volume":"81","author":"Zakhem","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"doi200055r47","doi-asserted-by":"publisher","DOI":"10.1159\/000505151","article-title":"Finasteride and suicide: a postmarketing case series.","author":"Irwig","year":"2019","journal-title":"Dermatology"},{"issue":"11","key":"doi200055r48","doi-asserted-by":"crossref","DOI":"10.5070\/D32311037240","article-title":"Sexual side effects of 5-a-reductase inhibitors finasteride and dutasteride: a comprehensive review.","volume":"23","author":"Fertig","year":"2017","journal-title":"Dermatol Online J"},{"issue":"4","key":"doi200055r49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1365-2125.2002.01569.x","article-title":"Non-sedating antihistamine drugs and cardiac arrhythmias\u2014biased risk estimates from spontaneous reporting systems?","volume":"53","author":"De Bruin","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"doi200055r50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32872\/cpe.v1i1.29642","article-title":"Evidence of a media-induced nocebo response following a nationwide antidepressant drug switch.","volume":"1","author":"MacKrill","year":"2019","journal-title":"Clin Psychol Eur"},{"issue":"2","key":"doi200055r51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s13300-018-0408-2","article-title":"Pharmacovigilance evaluation of the association between DPP-4 inhibitors and heart failure: stimulated reporting and moderation by drug interactions.","volume":"9","author":"Fadini","year":"2018","journal-title":"Diabetes Ther"},{"issue":"APR","key":"doi200055r53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1192\/bjp.154.4.478","article-title":"Social support and the outcome of major depression.","volume":"154","author":"George","year":"1989","journal-title":"Br J Psychiatry"},{"key":"doi200055r52","first-page":"891","volume-title":"J Psychosom Res","author":"Everson","year":"2002"},{"key":"doi200055r6","unstructured":"Levine D. Court let Merck hide secrets about a popular drug\u2019s risks. Published September 11, 2019. Accessed February 15, 2020. https:\/\/www.reuters.com\/investigates\/special-report\/usa-courts-secrecy-propecia\/"},{"key":"doi200055r7","unstructured":"Waters J. The drug that banishes baldness can ruin a man's love life: hair loss drug finasteride is used by millions, but men say it has devastating side-effects such IMPOTENCE that can last years after you've stopped taking it. Daily Mail Online. Published July 23, 2019. Accessed February 24, 2020. https:\/\/www.dailymail.co.uk\/health\/article-7274057\/How-baldness-drug-ruin-mans-love-life-Finasteride-devastating-effects.html"},{"key":"doi200055r8","unstructured":"Horovitz B. Why I\u2019d never take the hair loss drug President Trump uses. Published March 1, 2017. Accessed February 18, 2020. https:\/\/www.statnews.com\/2017\/03\/01\/trump-propecia\/"},{"key":"doi200055r9","unstructured":"MyHealthNewsDaily Staff. Hair-loss drug linked to severe depression in men. Updated August 7, 2012. Accessed March 6, 2020. http:\/\/www.nbcnews.com\/id\/48549905\/ns\/health-mens_health\/t\/hair-loss-drug-linked-severe-depression-men\/#.XmKrE0N7k1I"},{"key":"doi200055r10","unstructured":"Castillo M. Study of ex-Propecia users with sexual side effects finds increased risk for depression, suicidal thoughts. Published August 8, 2012. Accessed March 6, 2020. https:\/\/www.cbsnews.com\/news\/study-of-ex-propecia-users-with-sexual-side-effects-finds-increased-risk-for-depression-suicidal-thoughts\/"},{"key":"doi200055r11","unstructured":"Center for Drug Evaluation and Research. Approval package for NDA20-788\/S-017 (Propecia). Published March 11, 2011. Accessed January 10, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/020788Orig1s017.pdf"},{"key":"doi200055r12","unstructured":"Health Canada. Summary safety review\u2014Proscar and Propecia (finasteride). Published February 25, 2019. Accessed January 10, 2020. https:\/\/hpr-rps.hres.ca\/reg-content\/summary-safety-review-detail.php?lang=en&linkID=SSR00218"},{"key":"doi200055r13","unstructured":"Chu M. Ministry adds warnings to hair growth solution. Korea Biomed Rev. Published July 4, 2017. Accessed February 18, 2020. http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=812"},{"key":"doi200055r14","unstructured":"New Zealand Medicines and Medical Devices Safety Authority. Post-finasteride syndrome. Published March 2016. Accessed February 18, 2020. https:\/\/medsafe.govt.nz\/profs\/PUArticles\/March2016\/PostFinasterideSyndrome.htm"},{"key":"doi200055r15","unstructured":"Medicines and Healthcare Products Regulatory Agency. Finasteride: rare reports of depression and suicidal thoughts. Published May 24, 2017. Accessed February 18, 2020. https:\/\/www.gov.uk\/drug-safety-update\/finasteride-rare-reports-of-depression-and-suicidal-thoughts"},{"key":"doi200055r25","unstructured":"Uppsala Monitoring Center. VigiBase. Accessed February 18, 2020. https:\/\/www.who-umc.org\/vigibase\/vigibase\/"},{"key":"doi200055r42","unstructured":"Post-Finasteride Syndrome Foundation. About the Post-Finasteride Syndrome Foundation. Accessed March 6, 2020. https:\/\/www.pfsfoundation.org\/about-post-finasteride-syndrome-foundation\/"},{"key":"doi200055r43","unstructured":"Google Trends. Post-finasteride syndrome. Accessed March 21, 2020. https:\/\/trends.google.com\/trends\/explore?date=all&geo=US&q=post-finasteride%20syndrome"},{"key":"doi200055r44","unstructured":"Marshall L. The medical mystery behind America\u2019s best-selling hair-loss drug. Published November 21, 2016. Accessed February 18, 2020. https:\/\/www.vice.com\/en_us\/article\/gqywem\/the-medical-mystery-behind-americas-best-selling-hair-loss-drug"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2772818\/jamadermatology_nguyen_2020_oi_200055_1663623436.98514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:09:30Z","timestamp":1663758570000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2772818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3385","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}